A $2 share price is still ~$70mLet's put a PE ratio of 20 on...

A $2 share price is still ~$70m

Let's put a PE ratio of 20 on this (seems very cheap given the growth rate, but we'll run with it). At $70m, that implies earnings of $3.5m.

They have an 80%+ GM (CEO has suggested they can make improvements, but not a priority at this point). So let's use 80%.

A $3.5m after tax figure, at a 30% tax rate translates to $5m.
At an 80% GM, that's $6.25m of additional revenue required (from software revenues, not clinical services). That's ~90% growth.

Or, part of that could come from clinical services at ~50-60% margins. Let's say $2m PBT from here (~$4m revenue at 50%) plus another $1.5m from software (~$1.9m revenue).

An additional $5.9m revenues (+30%) on existing ARR of $20m is not a huge leap... (They did 22%+ in a COVID impacted environment)